How should congenital hypothyroidism be managed in a newborn, including initial levothyroxine dosing, monitoring schedule, and long‑term therapy considerations?

Management of Congenital Hypothyroidism

Start levothyroxine immediately at 10–15 mcg/kg/day as soon as congenital hypothyroidism is confirmed—preferably within the first 2 weeks of life—to prevent irreversible neurocognitive impairment. 1

Initial Treatment Decisions

When to Start Treatment

• Begin treatment immediately if venous free T4 is below the age-specific reference range 1
• Begin treatment immediately if venous TSH ≥ 20 mIU/L, even when free T4 is normal 1, 2
• For venous TSH 6–20 mIU/L beyond 21 days in a well infant with normal free T4, either start treatment immediately with plan for re-evaluation later, or retest in 2 weeks 1
• Never delay treatment to obtain imaging—thyroid imaging (ultrasound and/or scintigraphy) should be performed but must not postpone therapy initiation 1

Initial Levothyroxine Dosing

Use weight-based dosing that varies by age 1, 3:

• 0–3 months: 10–15 mcg/kg/day (use the higher end for severe disease with very low pretreatment T4/free T4) 1, 3
• 3–6 months: 8–10 mcg/kg/day 3
• 6–12 months: 6–8 mcg/kg/day 3
• 1–5 years: 5–6 mcg/kg/day 3
• 6–12 years: 4–5 mcg/kg/day 3

Special dosing considerations:

• Infants with pre-existing cardiac insufficiency should start at 50% of target dose, then increase gradually every 4–6 weeks 1
• Monitor closely for cardiac overload and arrhythmias during the first 2 weeks of therapy 3

Formulation and Administration

• Use brand-name levothyroxine tablets (not generic) in infancy, particularly for severe cases, as bioequivalence is not established 1
• Crush tablets and suspend in a few milliliters of water or breast milk for infants 1
• Administer consistently at the same time each day (morning or evening), either before or with feeding 1
• Avoid concurrent administration with soy, iron, calcium, or simethicone (found in colic drops), as these interfere with absorption 1, 4
• Exercise caution with vitamin D supplementation during the first weeks of treatment due to risk of hypercalcemia 1

Monitoring Schedule

First Year of Life (Most Critical Period)

Intensive monitoring is essential to achieve rapid TSH normalization and maintain free T4 in the upper half of the reference range 1:

• First follow-up: 1–2 weeks after starting treatment 1
• Until TSH normalizes: Every 2 weeks 1
• After TSH normalization through age 12 months: Every 1–3 months 1
• Blood samples must be drawn at least 4 hours after the last levothyroxine dose to avoid transient TSH suppression 1, 2

Ages 1–3 Years

• Monitor every 2–4 months with both clinical and laboratory evaluations 1, 2

After Age 3 Years Until Growth Completion

• Monitor every 3–12 months 1, 2
• Increase frequency if compliance is questioned, abnormal values occur, or after any dose or formulation change (recheck 4–6 weeks later) 1

Target Laboratory Values

• TSH: Maintain in age-specific reference range (avoid undetectable TSH <0.05 mIU/L) 1
• Free T4 or total T4: Maintain in the upper half of the age-specific reference range, especially during the first 3 years 1, 5
• Rapid normalization of thyroid hormone levels within the first 2 weeks leads to better intellectual outcomes 1
• Do not reduce levothyroxine dose based on a single elevated free T4 measurement 1

Long-Term Therapy Considerations

Re-evaluation of Diagnosis

Re-evaluation is indicated 1:

• When no diagnostic assessment was performed in infancy, particularly if the infant was preterm or sick at referral 1
• When initial imaging showed a normally located gland (with or without goiter) 1
• In children requiring no dose increase since infancy 1
• When maternal thyroid antibodies were present 1

Re-evaluation is NOT needed when thyroid dysgenesis (ectopy or athyreosis) was conclusively demonstrated on imaging, or when dyshormonogenesis was confirmed by genetic testing (except DUOX2 mutations or Pendred syndrome) 1

Timing and method of re-evaluation 1:

• Perform after age 3 years 1
• Phase out levothyroxine over 4–6 weeks, then perform full biochemical and imaging re-evaluation if hypothyroidism is confirmed 1
• Alternative approach: Decrease levothyroxine by 30% for 2–3 weeks; if TSH rises to ≥10 mIU/L, congenital hypothyroidism is confirmed 1

Developmental Monitoring

• Monitor psychomotor development and school progression in all children, particularly those at high risk 1
• High-risk features include: absent knee epiphyses at birth, very low initial T4/free T4, very high TSH at diagnosis, athyreosis, delayed TSH normalization, poor control during the first year, or delayed milestones 1
• Implement personalized educational plans if school progress is affected in severe cases 1

Compliance and Quality of Life

• Promote lifelong treatment compliance—suboptimal treatment in young adulthood carries risk of decreased health-related quality of life 1
• Provide written instructions to parents to avoid uncertainties that hinder compliance 1
• Avoid unnecessary "labeling" by not informing nursery or school educators unless medically necessary 1

Associated Conditions

• Examine all neonates with elevated TSH for congenital malformations (particularly cardiac defects) and dysmorphic features 1
• Consider knee X-ray to assess severity of intrauterine hypothyroidism by presence/absence of femoral and tibial epiphyses 1

Common Pitfalls

• Drug interactions: Over-the-counter medications like simethicone (in colic drops) can significantly impair levothyroxine absorption 4
• Macro-TSH: Consider polyethylene glycol precipitation testing if TSH remains disproportionately elevated despite adequate treatment and good compliance 4
• Overtreatment risk: Up to 20–25% of children may be overtreated after 12 months of therapy; avoid undetectable TSH levels 6
• Switching formulations: Recheck thyroid function 4–6 weeks after any switch from brand to generic levothyroxine 1
• Pregnancy in females with congenital hypothyroidism: Increase levothyroxine dose by 25–30% immediately upon missed menstrual cycle or positive pregnancy test; monitor TSH every 4–6 weeks during pregnancy 1